7 Questions to Ask Before Licensing a Vital Signs API

Procurement for camera-based vitals has shifted from a research curiosity into a real engineering decision, and the contracts now carry the weight to match. Licensing a vital signs API means committing your product roadmap, your data architecture, and often your regulatory posture to a third party whose internals you cannot inspect. The demo always works. A heart rate appears on screen in thirty seconds, the room is well lit, the subject sits still, and everyone nods. The hard questions start after that, when you have to predict how the same code behaves across ten thousand users on mid-tier Android phones in bad lighting. This report lays out the seven questions a technical buyer should put to any vitals vendor before signing, organized around the four pressures that actually break integrations: accuracy, latency, support, and pricing.

A non-contact photoplethysmography mobile application achieved a mean absolute error of 2.96 BPM for heart rate across 562 participants, while a separate clinical validation in cardiovascular patients reported 1.061 BPM against ECG. The gap between those two numbers is the entire due-diligence problem.

Why licensing a vital signs API demands structured due diligence

Remote photoplethysmography (rPPG) extracts a pulse signal from subtle color changes in skin captured by an ordinary RGB camera. The underlying science is sound, but published accuracy varies widely with conditions. A 2024 review of rPPG methods documented mean absolute errors anywhere from roughly 1 BPM in controlled clinical settings to figures that climb sharply at elevated heart rates and under motion. Researchers studying adaptive correction reported that in challenging scenarios median error fell from about 10 BPM to 5 BPM only after extra signal processing was applied. The lesson for a buyer is blunt: a single accuracy number on a marketing page tells you almost nothing without the conditions attached to it.

That variability is exactly why licensing a vital signs API should be treated as a structured evaluation rather than a feature checkbox. The questions below are ordered so that early answers filter out vendors before you waste engineering hours on a proof of concept.

Question 1: What are the accuracy numbers, and under what conditions were they measured?

Ask for the validation protocol, not the headline. A credible vendor will name the reference device (ECG, contact PPG, or a clinical-grade oscillometric cuff for blood pressure), the sample size, the demographic spread including skin tone (Fitzpatrick range), and the lighting and motion conditions. Insist on error metrics reported as mean absolute error and limits of agreement, not vague "clinical-grade" language. Ask specifically how accuracy degrades at high heart rates and on darker skin tones, because those are the documented failure modes in the literature.

Question 2: What is the end-to-end latency, and where does computation happen?

Latency is not one number. It is capture duration plus processing time plus network round trips. A thirty-second scan that then waits four seconds on a cloud inference call feels broken to a user. Ask whether processing runs on-device or server-side, what the p95 latency looks like on representative hardware, and how the system behaves under a degraded network. On-device inference protects privacy and cuts round trips but consumes battery and CPU; cloud inference centralizes model updates but introduces bandwidth dependency and a data-residency conversation.

Question 3: What does the licensing and pricing model actually charge for?

API pricing in 2025 trends toward tiered and subscription structures, but the unit of billing varies dangerously between vendors. Some charge per scan, some per monthly active user, some per seat, and some bundle a platform fee with usage overages. Model your real volume curve before you talk price, because a per-scan model that looks cheap in a pilot can become the dominant line item once a wellness feature gets used daily.

Comparing vital signs API licensing models

The table below frames the trade-offs technical buyers weigh when choosing a contactless vitals API. No single column is correct for every product; the right answer depends on your volume, your regulatory exposure, and how much control your team needs.

Evaluation axis	On-device SDK license	Cloud API (usage-based)	Hybrid SDK + managed service
Primary billing unit	Per app install or flat platform fee	Per scan or per API call	Platform fee plus metered overage
Data residency	Stays on device by default	Leaves device to vendor cloud	Configurable per deployment
Latency profile	No network round trip	Depends on bandwidth and region	Tunable, falls back to device
Offline support	Works offline	Requires connectivity	Degrades gracefully offline
Model update cadence	Tied to app release cycle	Instant, server-side	Mixed, server pushes plus SDK bumps
Best fit	Privacy-sensitive consumer apps	Low-volume or back-office tools	Regulated platforms at scale

Use the comparison as a filter. If your product is a privacy-sensitive consumer app, an on-device license aligns with your architecture. If you are running a telehealth back office at modest volume, usage-based cloud billing may be simpler to start.

Question 4: How responsive and technical is vendor support?

The integration that ships is rarely the integration that was demoed. Ask who answers the ticket when a build breaks at 2am: a named engineer, a shared queue, or a chatbot. Confirm the support tier included in your price, the response-time SLA, and whether you get access to people who actually wrote the signal-processing code. Request references from a customer at similar scale.

Question 5: What compliance and regulatory burden transfers to you?

This is where many deals get expensive. Depending on the claims you make, a vitals feature can fall under Software as a Medical Device (SaMD). Under the EU Medical Device Regulation, 2025 brought clearer software qualification rules and, for AI-driven products, overlapping obligations with the EU AI Act whose first provisions applied from February 2025. Industry estimates put compliance work at roughly 15 to 25 percent of healthcare software project cost, and an FDA SaMD pathway can run from tens of thousands of dollars into the millions with review timelines of 12 to 18 months. Ask the vendor exactly which certifications they hold, what documentation they will share for your own audit, and whether their accuracy claims are positioned as wellness or medical.

Question 6: How are data privacy and security handled?

Map the data flow before you sign. Ask whether raw video ever leaves the device, what is retained, for how long, and under which jurisdiction. Confirm support for HIPAA and GDPR obligations, encryption in transit and at rest, and whether you can sign a business associate agreement or data processing agreement. A vendor that processes frames on-device and discards them removes an entire category of breach risk from your roadmap.

Question 7: What does the exit look like?

Lock-in is the quiet cost. Ask about contract length, price-escalation clauses, what happens to your integration if the vendor is acquired or sunsets a model, and whether you can export historical measurements in an open format. A clean exit clause is a sign of a vendor confident in retention through quality rather than friction.

Industry Applications

Telehealth and remote patient monitoring

Clinical-adjacent products carry the heaviest compliance load and the lowest tolerance for latency or inaccuracy at elevated heart rates. For these buyers, Questions 1 and 5 dominate, and a hybrid deployment with configurable data residency usually wins.

Wellness and consumer fitness

Consumer apps prioritize frictionless on-device experiences and predictable per-user economics. Questions 2 and 3 carry the most weight, and accuracy claims should stay firmly in the wellness category to avoid triggering medical-device obligations.

Insurance and corporate health

Insurers and employee-benefit platforms run high scan volumes in bursts. The pricing model in Question 3 and the exit terms in Question 7 determine whether the unit economics hold as adoption scales.

Current research and evidence

The peer-reviewed record now gives buyers concrete benchmarks rather than vendor assertions. The 562-participant study on a non-contact PPG mobile application (published in PMC) reported a 2.96 BPM mean absolute error for heart rate, a realistic figure for consumer conditions. A separate clinical validation of rPPG-enabled contactless pulse monitoring in cardiovascular disease patients achieved 1.061 BPM against ECG, demonstrating what controlled settings allow. Work on adaptive physiology-informed correction (PMC, 2024) showed that post-processing can halve median error in difficult scenarios. Taken together, these results confirm that rPPG accuracy is real but conditional, which is precisely why Questions 1 and 2 should anchor any evaluation. When you evaluate an rPPG SDK, ask the vendor to map their numbers onto this published range.

The future of vital signs API licensing

Three shifts are reshaping how these contracts get written. First, regulatory convergence: with MDR clarifications and the EU AI Act phasing in through 2025 and 2026, vendors will increasingly compete on the documentation they hand buyers, not just on raw accuracy. Second, on-device inference is becoming the default for privacy-sensitive deployments as mobile silicon improves, pushing the architecture conversation toward edge-first designs. Third, pricing transparency is rising as the market matures, which gives buyers more use to negotiate volume terms and exit clauses. Teams that build a repeatable due-diligence checklist now will move faster on every future vendor cycle.

Frequently asked questions

What is the single most important question when licensing a vital signs API?

Accuracy under realistic conditions. A vendor that will only share a headline number without the validation protocol, sample size, skin-tone range, and motion conditions has not earned a proof of concept. Everything else follows from trustworthy measurement.

Does a contactless vitals API make my product a regulated medical device?

It depends on your claims. Wellness and informational framing generally stays outside Software as a Medical Device rules, while diagnostic or monitoring claims can trigger MDR or FDA obligations. Confirm with the vendor which category their accuracy claims support, and get your own regulatory review before launch.

Should processing happen on-device or in the cloud?

On-device inference reduces latency and keeps raw video off the network, which simplifies privacy compliance. Cloud processing centralizes model updates and offloads computation. Many regulated platforms choose a hybrid that keeps frames local while syncing results, so match the choice to your data-residency and latency needs.

How should I compare pricing across vitals vendors?

Normalize every quote to your real usage curve. Convert per-scan, per-user, and platform-fee models into a projected annual cost at expected volume, then add the compliance and integration overhead. The cheapest pilot price is rarely the cheapest production price.

Circadify is building developer tooling for this exact evaluation: a drop-in rPPG SDK that lets engineering teams add contactless vitals in days rather than months, with on-device processing and documentation aimed at technical due diligence. If you are working through this checklist for a real integration, request developer docs and API keys at circadify.com/custom-builds and run the seven questions against a live build.